Mangoes for Inflammation

Phase-Based Progress Estimates
Appalachian State University Human Performance Lab, North Carolina Research Campus, Kannapolis, NC
Inflammation+2 More
Mangoes - DietarySupplement
18 - 65
All Sexes
What conditions do you have?

Study Summary

Vigorous exercise bouts result in significant inflammation and muscle soreness. Our research group has published several papers showing that ingestion of various types of fruits enhances inflammation resolution after exercise. Mangoes have a unique nutrient profile (carotenoids, polyphenols, sugars, vitamins) that we hypothesize will mitigate post-exercise inflammation and muscle soreness. This study will examine the effect of 2 cups/day frozen mango ingestion (2 weeks, 330 g/day) in moderating exercise-induced (2.25 h cycling) inflammation and muscle soreness in a randomized crossover trial. Participants will include 20 male and female young adult cyclists (ages 18-45 years) who are capable of cycling 2.25 h in the laboratory on trainers. In random order, the cyclists will supplement their diets with 2 cups/day mangoes with 1 cup water or 1 cup water alone for two weeks, followed by the 2.25-h exercise challenge. Blood and urine samples will be collected pre- and post-2 weeks supplementation. Additional blood samples will be collected immediately post-exercise, and then 1.5-h, 3-h, and 24-h post-exercise. Urine samples will be analyzed for mango-related metabolites to confirm compliance to the supplementation regimen and to establish statistical relationships with inflammation-related outcomes. The blood samples will be analyzed for novel, cutting-edge outcomes related to inflammation including 70 oxylipins, inflammasome activation, and pro-inflammatory cytokines that we have previously shown are sensitive to exercise and nutrition-based interventions. If the data support our hypothesis, mango ingestion will be viewed as a nutritional strategy to counter exercise-induced inflammation by fitness enthusiasts and athletes who exercise vigorously on a regular basis.

Eligible Conditions

  • Inflammation
  • Muscular Injury
  • Inflammatory Responses

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Inflammation

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Change from pre-study to post-2 weeks supplementation, and immediately post-exercise, and 1.5 hours-, 3 hours-, and 24 hours-post-exercise

Week 2
Urine mango metabolites
Week 2
Plasma inflammasome activation
Plasma lipid mediators

Trial Safety

Safety Progress

1 of 3

Other trials for Inflammation

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Mangoes · No Placebo Group · N/A

Experimental Group · 1 Intervention: Mangoes · Intervention Types: DietarySupplement
ActiveComparator Group · 1 Intervention: Water · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from pre-study to post-2 weeks supplementation, and immediately post-exercise, and 1.5 hours-, 3 hours-, and 24 hours-post-exercise
Closest Location: Appalachian State University Human Performance Lab, North Carolina Research Campus · Kannapolis, NC
2014First Recorded Clinical Trial
6 TrialsResearching Inflammation
10 CompletedClinical Trials

Who is running the clinical trial?

Appalachian State UniversityLead Sponsor
35 Previous Clinical Trials
1,927 Total Patients Enrolled
10 Trials studying Inflammation
424 Patients Enrolled for Inflammation
David C Nieman, DrPHPrincipal InvestigatorAppalachian State Univ
10 Previous Clinical Trials
563 Total Patients Enrolled
3 Trials studying Inflammation
164 Patients Enrolled for Inflammation

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male or female cyclist, aged 18-45 years, and capable of cycling 2.25 h in the lab on trainers at 70% VO2max (close to race pace).
You are a non-smoker, and generally healthy and without chronic disease including cardiovascular disease (e.g., heart disease, stroke), cancer, type 1 and 2 diabetes, rheumatoid arthritis.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.